Eosinophilia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
George Leef (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Eosinophilia}} | {{Eosinophilia}} | ||
*Eosinophilia is a laboratory finding and is not specifically a target of treatment in most cases | |||
*If the severely elevated eosinophilia count is felt to be the cause of the patient's symptoms, there are a number of treatments that specifically lower eosinophil counts | |||
*Anti-IL5 antibody [[mepolizumab]] is under investigation for use in hypereosinophil syndrome. Mepolizumab has shown potential to rapidly reduce eosinophil counts in trials and reduce the need for corticosteroids. <ref>Rothenberg et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. NEJM 2008; 358:1215-1228</ref> | |||
[[Category:Laboratory Test]] | [[Category:Laboratory Test]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Blood tests]] | [[Category:Blood tests]] | ||
Revision as of 22:37, 29 August 2016
|
Eosinophilia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Eosinophilia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Eosinophilia future or investigational therapies |
|
Eosinophilia future or investigational therapies in the news |
|
Risk calculators and risk factors for Eosinophilia future or investigational therapies |
- Eosinophilia is a laboratory finding and is not specifically a target of treatment in most cases
- If the severely elevated eosinophilia count is felt to be the cause of the patient's symptoms, there are a number of treatments that specifically lower eosinophil counts
- Anti-IL5 antibody mepolizumab is under investigation for use in hypereosinophil syndrome. Mepolizumab has shown potential to rapidly reduce eosinophil counts in trials and reduce the need for corticosteroids. [1]
- ↑ Rothenberg et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. NEJM 2008; 358:1215-1228